BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 35640927)

  • 1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
    Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
    Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
    Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
    Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
    Kelly RJ; Bever K; Chao J; Ciombor KK; Eng C; Fakih M; Goyal L; Hubbard J; Iyer R; Kemberling HT; Krishnamurthi S; Ku G; Mordecai MM; Morris VK; Paulson AS; Peterson V; Shah MA; Le DT
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
    Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
    Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
    Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
    J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
    Galsky MD; Balar AV; Black PC; Campbell MT; Dykstra GS; Grivas P; Gupta S; Hoimes CJ; Lopez LP; Meeks JJ; Plimack ER; Rosenberg JE; Shore N; Steinberg GD; Kamat AM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
    Hann CL; Scherpereel A; Hellyer JA; Wakelee HA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():543-552. PubMed ID: 31099677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of immune checkpoint inhibitors in thoracic malignancies.
    Remon J; Facchinetti F; Besse B
    Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34615702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
    Kindler HL; Ismaila N; Armato SG; Bueno R; Hesdorffer M; Jahan T; Jones CM; Miettinen M; Pass H; Rimner A; Rusch V; Sterman D; Thomas A; Hassan R
    J Clin Oncol; 2018 May; 36(13):1343-1373. PubMed ID: 29346042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2037-2074. PubMed ID: 37455124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):539-574. PubMed ID: 37460438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.